← Back to Search

Patient-Reported Outcomes Monitoring for Kidney Cancer Treatment Side Effects (PRO-VISION Trial)

N/A
Waitlist Available
Led By Tracy Rose
Research Sponsored by UNC Lineberger Comprehensive Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Histologically confirmed renal cell carcinoma requiring treatment with VEGF TKI
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 3 years
Awards & highlights
No Placebo-Only Group

Summary

This trial explores how collecting patient data directly can help manage side effects of oral chemo for mRCC. Patients will complete weekly surveys and be contacted when symptoms worsen. Through this trial, researchers hope to improve patient care.

Who is the study for?
This trial is for adults with renal cell carcinoma who need VEGF TKI treatment. They must be able to complete surveys in English or Spanish and have internet or phone access. Those unable to do the surveys are excluded.
What is being tested?
The study tests if monitoring side effects through weekly patient-reported outcomes via survey can help manage symptoms from oral VEGFR TKI chemotherapies used in metastatic kidney cancer.
What are the potential side effects?
There are no direct side effects from participating in the study itself, but it monitors common side effects of VEGFR TKIs like nausea and fatigue.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My kidney cancer needs treatment targeting blood vessel growth.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 3 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 3 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Relative dose intensity
Secondary study objectives
Adherence to Patient Reported Outcome -based symptom
Dose interruption
Dose modifications
+10 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Patient PerspectiveExperimental Treatment1 Intervention
Study participants will complete several questionnaires/assessments related to adverse events and quality of life.

Find a Location

Who is running the clinical trial?

UNC Lineberger Comprehensive Cancer CenterLead Sponsor
363 Previous Clinical Trials
91,966 Total Patients Enrolled
Doris Duke Charitable FoundationOTHER
64 Previous Clinical Trials
264,368 Total Patients Enrolled
Tracy RosePrincipal InvestigatorUNC Lineberger Comprehensive Cancer Center

Media Library

Patient Perspective Clinical Trial Eligibility Overview. Trial Name: NCT05592665 — N/A
Kidney Cancer Research Study Groups: Patient Perspective
Kidney Cancer Clinical Trial 2023: Patient Perspective Highlights & Side Effects. Trial Name: NCT05592665 — N/A
Patient Perspective 2023 Treatment Timeline for Medical Study. Trial Name: NCT05592665 — N/A
~18 spots leftby Jan 2027
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top